Results 1 to 10 of about 33,574 (228)
Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies [PDF]
Lewy body dementia is the second most common form of neurodegenerative dementia, following Alzheimer’s disease. This umbrella term encompasses dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD).
Dennis W. Dickson +2 more
exaly +3 more sources
Evidence for divergent cortical organisation in Parkinson’s disease and Lewy Body Dementia [PDF]
Dementia is a defining feature of Lewy body disease: its timing and onset distinguish different clinical diagnoses, and its effect on quality of life is profound.
Angeliki Zarkali +7 more
doaj +2 more sources
Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology
Ubiquitin Specific Protease-13 (USP13) promotes protein de-ubiquitination and is poorly understood in neurodegeneration. USP13 is upregulated in Alzheimer’s disease (AD) and Parkinson’s disease (PD), and USP13 knockdown via shRNA reduces neurotoxic ...
Xiaoguang Liu +5 more
doaj +1 more source
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium
The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and ...
Gregory D. Scott +54 more
doaj +1 more source
Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies
Introduction Bosutinib, a dual Abelson/Src inhibitor, was investigated in individuals with dementia with Lewy bodies (DLB). Methods A single site, randomized, double‐blind, placebo‐controlled study of the effects of oral bosutinib, 100 mg once daily for ...
Fernando L. Pagan +8 more
doaj +1 more source
Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting
In 2019, the Lewy Body Dementia Association formed an Industry Advisory Council to bring together a collaborative group of stakeholders with the goal of accelerating clinical research into Lewy body dementia treatments.
Jennifer G. Goldman +18 more
doaj +1 more source
Background: Lewy body dementia, comprising both dementia with Lewy bodies and Parkinson’s disease dementia, is the second commonest cause of neurodegenerative dementia.
John T O’Brien +17 more
doaj +1 more source
Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice.
John T. O’Brien +5 more
doaj +1 more source
Sex differences in clinical cognitive impairment with Lewy bodies: a Chinese multicenter study
Highlights There are significant sex differences in Chinese population with cognitive impairment in Lewy body disease. Women were more common in dementia with Lewy bodies and mild cognitive impairment with Lewy bodies cases, had more frequent and severe ...
Jinghuan Gan +15 more
doaj +1 more source
The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator’s meeting was held on December 14, 2017, in New Orleans.
Bethany Peterson +44 more
doaj +1 more source

